Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Metabolomics reveals LysoPC a C17:0 (LPC 17:0) as candidate biomarker for personalized medicine in morbid obesity.

Frontiers in medicine·2026

Same author

Effect of sleep quality on vision-related quality of life in a sample of Qassim University students: an ocular surface health approach.

PeerJ·2025

Same author

Novel protocol for metabolomics data normalization and biomarker discovery in human tears.

Clinical chemistry and laboratory medicine·2025

Same author

Association Between Dry Eye Disease with Anxiety and Depression Among Medical Sciences Students in Qassim Region: Cortisol Levels in Tears as a Stress Biomarker.

Journal of multidisciplinary healthcare·2024

Same author

Ocular Surface Health in Connection with Anxiety and Depression: a Review.

Journal of multidisciplinary healthcare·2024

Same author

Systemic treatment with cigarette smoke extract affects zebrafish visual behaviour, intraocular vasculature morphology and outer segment phagocytosis.

Open research Europe·2024

Search research articles

Related Experiment Video

Updated: May 3, 2026

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Published on: November 1, 2024

Recent developments on dry eye disease treatment compounds.

Basilio Colligris¹, Hanan Awad Alkozi¹, Jesus Pintor¹

¹Departamento de Bioquímica y Biología Molecular IV, Facultad de Óptica y Optometría, Universidad Complutense de Madrid, C/Arcos de Jalón 118, 28037 Madrid, Spain.

Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society

|February 15, 2014

Summary

New pharmaceutical compounds, including secretagogues and anti-inflammatory drugs, offer novel therapeutic strategies for managing dry eye syndrome by reducing inflammation and restoring a healthy tear film.

Keywords:

Anti-inflammatory Dry eye Keratitis sicca Keratoconjunctivitis sicca Mucin secretion NSAID Tear secretion Xerophthalmia

More Related Videos

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

Related Experiment Videos

Last Updated: May 3, 2026

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Published on: November 1, 2024

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

Area of Science:

Ophthalmology
Pharmacology

Background:

Dry eye syndrome is a multifactorial ocular surface disease characterized by reduced tear quantity and sensitivity, leading to inflammation.
Current treatments include artificial tears, tear retention, tear secretion stimulation, and anti-inflammatory drugs.

Purpose of the Study:

To review novel and future pharmaceutical compounds for dry eye disease treatment.
To identify emerging therapeutic strategies targeting key inflammatory pathways.

Main Methods:

Literature and patent review of pharmaceutical compounds for dry eye disease.
Analysis of compounds targeting inflammatory pathways and tear film restoration.

Main Results:

Secretagogues and anti-inflammatory drugs are the most frequent categories of novel compounds.
These compounds represent new therapeutic strategies for dry eye disease.

Conclusions:

Novel pharmaceutical compounds show promise in managing dry eye disease.
Future treatments focus on reducing inflammation and restoring ocular surface health.